Gold Standard Diagnostics Expands ThunderBolt® Laboratory Automation International Sales and Marketing Network
Strong domestic and international sales expected for 2013 and beyond.
Davis, CA, March 19th, 2013 – Gold Standard Diagnostics, Corp. (GSD, www.gsdx.us), a leading manufacturer and marketer of clinical laboratory instrumentation and assays for the in vitro diagnostics market, today announced it has established distribution partnerships for the ThunderBolt® Automated Immunoassay Analyzer in 18 countries throughout Europe, Latin America, Asia and the Middle East since the official global launch in early 2012. ThunderBolt® sales in the U.S. market also continue to grow as laboratories recognize the powerful and seamless automation solutions that Gold Standard Diagnostics offers.
Mature and emerging markets alike have responded to the comprehensive suite of fully automated features that the compact and cost-effective ThunderBolt® offers. As a result, the global sales and marketing network has grown substantially over the past year. Established markets, such as those in Europe, have widely accepted the ThunderBolt® with installations in Germany, Spain, Finland, Austria, Switzerland and Belgium. Additional countries with installed units include South Korea, Mexico, Vietnam, and Puerto Rico. Distribution partnerships and sales in China, Brazil, India and Canada are also imminent.
Streamline Parasitology Testing With Reliable Procurement and Broad Product Offering
Hard-to-find parasite and worm assays delivered on time by Gold Standard Diagnostics.
November 14th, 2012, Davis, CA – Simplify parasitology testing with Gold Standard Diagnostics’ (GSD) comprehensive line of assays for parasites and worms. GSD’s extensive portfolio of parasite tests provides laboratories with a reliable, single-source procurement option and access to a wide range of highly-consistent and cost-effective serological and stool assays.
In Wake of Fungal Meningitis Outbreak, Laboratories Must Prepare for Increased Aspergillus Testing Demand
Laboratories Must Prepare for Increased Aspergillus Testing Demand in Wake of Fungal Meningitis Outbreak
Full line of Aspergillus fumigatus ELISA test options available from Gold Standard Diagnostics.
October 9th, 2012, Davis, CA – Gold Standard Diagnostics’ (GSD) comprehensive line of Aspergillus diagnostic tests enables clinical laboratories to prepare as the number of Aspergillus tests ordered is expected to rise significantly in the wake of 17,676 vials of potentially fungus-tainted steroids that have been recalled.
GSD’s complete solution for detection of Aspergillus IgG, IgM and IgA antibodies enables accurate detection of the fungus related to the current proliferation of fungal meningitis. The number of confirmed cases now exceeds 100 across 23 states, and many more cases are possible as symptoms may take up to a month to emerge. Laboratories should immediately procure sufficient Aspergillus tests to meet this expected increase in demand.
Enhance Free Testosterone Testing with FDA Cleared Direct Detection
Eliminate extra steps, save time and money.
Davis, CA, September 5th, 2012 – Simplify and improve your clinical laboratory with single-step, direct ELISA measurement of Free Testosterone from Gold Standard Diagnostics (GSD). Compared to indirect, multi-step testing algorithms, GSD’s FDA Cleared Free Testosterone products save time and money while reducing the possibility of errors.
Reduce errors and cost with single-step Free Testosterone…
The ability to directly measure Free Testosterone eliminates the complication of taking multiple indirect measurements and calculating Free Testosterone through an algorithm. Diagnostic technologies have inherent limitations in terms of both precision and accuracy. Combining multiple procedures exacerbates these limitations and increases both the cost and opportunity for errors.
Autoimmune Multiplex: Reduce Costs and Increase Throughput
Reduce Costs and Increase Throughput for Autoimmune Diagnostic Testing Using Multiplex Technology
Generate multiple results and revenue from a single well.
Davis, CA, August 7th, 2012 – Simplify clinical diagnosis of autoimmune disease with Gold Standard Diagnostics’ (GSD) comprehensive offering of multiplex autoimmune assays. GSD has partnered with Theradiag (formerly known as Biomedical Diagnostics, BMD) to provide laboratories with the FIDIS™ suite of products for detection of the autoantibodies associated with connective tissue diseases, CREST syndrome, lupus erythematosus, rheumatoid arthritis, vasculitis, polymyositis, dermatomyositis, scleroderma, Sjögren syndrome, thyroid syndromes, Celiac and many others. Major benefits of the FIDIS™ multiplex product suite include: up to 13 results in a single well, reduced labor and overhead, increased throughput, small sample volume and full automation.
Simplify Your Laboratory Experience with Multiplex…
AACC Recap: An Exciting Year for GSD
The 2012 AACC Lab Expo was the biggest year yet for Gold Standard Diagnostics. The huge response to the ThunderBolt® EIA+CLIA Platform, our Extensive Product Menu and Outstanding Customer Service was extremely exciting. We look forward to working with each of you to Simplify Your Laboratory Experience!
We will be sorting through all of the new contacts we made and following up over the next few weeks. In the meantime, please don't hesitate to contact us with any questions you may have about our instrumentation, reagents, service or company in general.
More Articles...
- CLIA Now Available! Boost Clinical Lab Efficiency with the ThunderBolt® EIA+CLIA Automation Platform
- Newest FDA-Cleared H. pylori Kit on the Market
- Gold Standard Diagnostics Lyme Disease LIA FDA Cleared
- Bordetella Pertussis: GSD Alerts Clinical Laboratories to Prepare for Continued Outbreaks
- Gold Standard Diagnostics Announces Global Launch of New, Fully Automated ELISA Platform ThunderBolt
- Gold Standard Diagnostics Launches Axis-Shield’s New and Improved Anti-CCP2 Assay for Early and Accurate Diagnosis of Rheumatoid Arthritis
- Gold Standard Diagnostics Extends Relationship with Fujirebio Diagnostics, Inc. and Signs an Exclusive US Distribution Agreement for Cyfra 21-1 EIA
- FDA Clears Next-Generation Biomarker Test to Determine Likelihood of Ovarian Cancer in Women who Present with Adrenal Mass
- Gold Standard Diagnostics Signs U.S. Distribution Agreement with Fujirebio Diagnostics for Multi-Constituent Tumor Marker Control
- Gold Standard Diagnostics Introduces the ThunderBolt Automated Diagnostics Platform
- Gold Standard Diagnostics Signs Exclusive US Distribution Agreement with Axis-Shield for Homocysteine